Learning Hub

Clinical experts team Gail Heritage University of Oxford Position Senior Research Manager What is your role in iPROLEPSIS? UK PDPID coordinating center Manager What are your main activities in the project? UK Study manager What is your motivation? Contribution to clinical research to enhance patient experiences and disease outcomes. Francesca Levi-Schaffer The Hebrew University of Jerusalem, Israel Position Professor What is your role in iPROLEPSIS? Researcher What are your main activities in the project? To try to understand the passage from psoriasis to psoriatic arthritis by evaluating in skin biopsies vascularization, mast cell presence and to correlate this with involved joint vascularization What is your motivation? I would like to discover the connections between skin and joints and find a drug/s that can inhabit this progression Laura Coates Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Position NIHR Research Professor What is your role in iPROLEPSIS? Lead for WP5 (clinical studies) What are your main activities in the project? I oversee all of the clinical studies within the consortium. What is your motivation? I am a rheumatologist who has worked in research in psoriatic arthritis for around 20 years. My interest is in improving outcomes for people living with psoriatic arthritis and I believe that work in this project can help us to predict, monitor and understand the disease better in day to day clinics. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Download iProlepsis project applications for psoriatic arthritis. Apps for download miPROLEPSIS app The miPROLEPSIS app facilitates the iPROLEPSIS-PDPID multicenter clinical study as a data collection tool that will enable the development of digital biomarkers for psoriatic arthritis symptoms and predictive models for inflammation exacerbation. More specifically, the app performs (i) passive data collection from the sensors of the smartwatch used in the study (i.e., Garmin Vivoactive 5), (ii) passive data collection from the accelerometer and gyroscope sensors of the smartphone, (iii) patient reported outcomes via questionnaires. Moreover, the app includes (i) a custom keyboard that captures the user’s typing dynamics and (ii) photo- and video-based activities for the collection of hand/feet photos and skeletal data related to joints flexibility, respectively. Note: The app can be used only by psoriatic arthritis patients that have enrolled to the PDPID study. This enrollment is available for patients in the UK, Netherlands, Portugal, and Greece. Information on how to enroll in the study and gain access to the miPROLEPSIS app will be provided soon. miPROLEPSIS app The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS Joint Landmarker app The miPROLEPSIS Joint Landmarker is an accompanying app of the miPROLEPSIS app that enables the video-based active tests feature. More specifically, a set of 6 hand and body movement exercises are presented and the user is asked to perform them in front of the smartphone camera. The app captures the videos and extracts skeletal data (coordinates of skeletal joints) locally. The skeletal data will be further analysed to develop digital biomarkers that assess the functionality and flexibility of joints. Note: The miPROLEPSIS Joint Landmarker app cannot be used without the miPROLEPSIS app. miPROLEPSIS Joint Landmarker app This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. The videos are immediately discarded and no personal information is retained, saved or transmitted.

< BACK Digital Innovation for Psoriatic Arthritis Prevention Sep 11, 2025 An interview with iPROLEPSIS coordinators in Thessalonikeon Polis on how digital tools, wearables, and AI can help prevent psoriatic arthritis In a recent interview with Thessalonikeon Polis , Vasilis Charisis and Project Coordinator Prof. Leontios Hadjileontiadis from the Signal Processing & Biomedical Technology Unit – AUTH shared insights on the iPROLEPSIS project. The interview highlights the iPROLEPSIS project, showing how smartphones and wearables can assist in early detection and prevention of psoriatic arthritis through digital tools such as wearables, educational games, and personalised apps. It also touches on AI in healthcare, stressing its role in supporting – not replacing – healthcare professionals. Read the full article (in Greek): https://thessalonikeonpolis.gr/machi-kata-tou-parkinson-tehniti-noimosini/ iPROLEPSIS_interview.png iPROLEPSIS_interview.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 7 Jan 28, 2025 Latest News from iPROLEPSIS Welcome to the 7th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_Jan 2025_Issue No. 7 .pdf Download PDF • 5.60MB 1/1 PREVIOUS NEXT

Coordination team Vasilis Charisis Signal Processing & Biomedical Technology Unit (SPBTU) – Aristotle University of Thessaloniki Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Scientific and Technical Coordinator. What are your main activities in the project? I manage the project's day-to-day operations and scientific coherence, driving the timely delivery of outcomes. Our team (SPBTU) is pioneering the use of AI and digital biomarkers from everyday smart devices to create predictive models for PsA symptoms. We are also developing a dedicated mobile app that supports patients by improving sleep patterns using binaural beat technology. What is your motivation? My motivation is rooted in a long-standing commitment to improving chronic disease management through accessible, non-invasive technology. In iPROLEPSIS, I am driven to apply advanced AI and biomedical engineering principles to address the significant challenges faced by PsA patients. We aim to create tangible, personalized digital tools that not only predict disease flares early but actively enhance patients' quality of life, ensuring our cutting-edge research delivers real clinical benefits. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK World Psoriasis Day: iPROLEPSIS featured by HaDEA Oct 29, 2025 On World Psoriasis Day, the European Health and Digital Executive Agency (HaDEA) highlights how the iPROLEPSIS project is advancing early detection and personalised care for psoriatic arthritis Psoriatic arthritis (PsA) is a chronic inflammatory condition that can cause irreversible joint damage if left undiagnosed or untreated. To address this challenge, iPROLEPSIS is developing AI-driven predictive models and digital tools that help identify individuals at risk, enable earlier diagnosis, and support more personalised treatment pathways. In a recent interview with Prof. Leontios Hadjileontiadis , project coordinator, HaDEA explores how iPROLEPSIS brings together clinicians, researchers, and data scientists to transform psoriatic arthritis management across Europe. The discussion covers the project’s use of AI and biological data to build comprehensive patient profiles, its collaborative approach between dermatology and rheumatology, and the importance of EU funding and ethical, cross-border cooperation in enabling innovation. Read the full article on HaDEA’s website: https://hadea.ec.europa.eu/news/world-psoriasis-day-exploration-how-horizon-europe-project-improving-early-detection-psoriatic-2025-10-29_en World Psoriasis Day 2025.png World Psoriasis Day 2025.png 1/1 PREVIOUS NEXT

Download needed deliverables for iProlepsis project for psoriatic arthritis. Project deliverables D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Read More D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Read More D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Read More D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Read More D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Read More D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Read More D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Read More D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Read More D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Read More

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Living with Psoriatic Arthritis Handbook How will psoriatic arthritis affect me? WORK Work can provide a sense of purpose, identity, achievement, and a supportive social network, contributing positively to your emotional and physical wellbeing. While your condition may pose some challenges, people living with psoriatic arthritis can continue to work as long as their profession does not exacerbate their symptoms and worsen their health. People with certain health conditions have defined rights set out in law, designed to protect them against direct and indirect discrimination in the workplace. Your employer is legally obligated to make “reasonable accommodations” to your working environment and practices to ensure your condition does not prevent you from doing your job to the best of your ability and in a comfortable and safe environment. h3.1 In the European Union, the definition of reasonable accommodation at work was introduced by Article 5 of the Employment Equality Directive (Directive 2000/28/EC): “shall take appropriate measures, where needed in a particular case, to enable a person with disability to have access to, participate in, or advance in employment, or to undergo training, unless such measures would impose a disproportionate burden on the employer.” This directive has been transposed into national law in all EU member states. Research has shown that people who need workplace accommodations and effectively use them are more likely to keep a job and stay productive than those who do not use workplace accommodations (39). However, asking for workplace accommodations can be difficult. You may be concerned about being treated differently and negative reactions from your supervisor(s) or colleague(s). For this reason, you may prefer to negotiate informal workplace accommodations rather than seeking formal accommodations. Some of these accommodations may include those supported by the American College of Sports Medicine guidelines for physical activity and public health (40) and the ISO 11226 standard , https://www. iso.org/standard/25573.html , which defines joint limits to safeguard musculoskeletal health. By aligning workplace practices with these scientifically supported guidelines, employers and healthcare professionals can better accommodate the needs of their employees, fostering an inclusive and supportive work environment. Some examples follow: Recommendation #1: Avoid working for prolonged periods in the same position, whether sitting or standing. During the work shift: a continuous period of time in the standing position should not exceed 1 hour; the total time spent in a standing position should not exceed 4 hours; continuous sitting should be limited to 2 hours; when periods are dedicated to holding meetings, the duration of which should be reasonable, consideration should be given to the possibility of having them while standing or walking (41). Recommendation #2: Take frequent breaks throughout the shift. Please note that he definition of “breaks” must consider the following characteristics: Frequency: number of breaks/interruptions during the working day; Duration: micro-breaks (less than 2 minutes); short breaks (typically those that occur in the morning or afternoon, lasting between 7 and 10 minutes); or long breaks (meal breaks); and Type: passive or resting and active (including stretching or walking) (42). Thus, in an 8-hour working day, a worker should take at least a 7–10-minute break after consecutive 90-minute work periods. Recovery periods can include moments of rest or the performance of any other task to recover the muscle groups that have been worked. Within a period of at least 90 minutes, a worker should enjoy at least 30 seconds after 20 minutes of work. Both recommendations aim to address the prolonged exposure to low-intensity static load by limiting the duration of this exposure. These interventions help to alleviate fatigue and pain symptoms in the short-term, and to prevent work-related musculoskeletal injuries in the long-term. Active breaks add value; however, they do not replace the need to introduce diversity in the intensity of the mechanical load, such as rotational planes suited to the job’s demands (43). Please note that these recommendations refer to low-intensity, physically demanding tasks. Other recommendations apply to high-intensity tasks, such as those involving manual force. Recommendation #3: Physical changes to workstations work surfaces (desks) that allow alternation between standing and sitting, alone or combined with a training and information program for workers, reduce sitting time by approximately 60 minutes per working day (in the medium term, i.e., up to 3-12 months). This change in physical working conditions can bring about a behavioural change, with repercussions in an average reduction of 82 minutes in total sitting time per day (at and away from work) and in the average duration of consecutive periods of sitting (57 minutes) (42, 44). Even though workplace adaptations are consigned in the law, many people living with rheumatic and musculoskeletal diseases report a lack of understanding from their employer(s), colleague(s), and workplace doctor(s). You have options and rights; it is important to understand them and fully explore all available alternatives. If you are unsure about your rights in the workplace, please get in touch with your HR or occupational health department. More information can be found below: The Advisory, Conciliation and Arbitration Service. (ACAS) https://www.acas.org.uk/reasonable-adjustments If you require workplace adaptations, please talk to your assistant doctor about the difficulties you have been feeling and request reports to present to your employer and/or workplace doctor. See related Key Facts section SLEEP Pain, anxiety, and side effects of the medication can make it more difficult for a person with psoriatic arthritis to fall asleep and stay asleep throughout the night. In fact, about 40% of people living with psoriatic arthritis report sleep difficulties (45). Good sleep hygiene habits may help to improve sleep: develop a regular sleep routine, that is, go to bed and get up at a similar time each day; avoid caffeine, alcohol, and large meals before you go to bed; if you smoke, try to stop smoking, or at least do not smoke close to bedtime; a warm bath before bedtime may help ease pain and stiffness; listen to soothing music or sounds before going to bed; avoid watching TV and using computers, tablets, or smartphones in your bedroom; make sure your bedroom is dark, quiet, relaxing, and at a comfortable temperature. h3.2 The impact of exercising before bedtime can vary among individuals. It is essential to listen to your body, establish a consistent routine, and pay attention to how evening workouts affect your sleep patterns. If you have specific concerns about your sleep or exercise routine, it is also advisable to consult with a healthcare professional or a fitness expert. Pros: Improved sleep quality: For some people, engaging in moderate-intensity exercises a few hours before bedtime may promote better sleep quality. It can help reduce stress and anxiety, leading to a more relaxed state conducive to sleep. Body temperature regulation: Exercise increases body temperature, and the subsequent drop in temperature after exercise can signal the body that it is time to sleep. This mimics the natural temperature drop that occurs during the evening. Establishing a routine: Regular exercise, regardless of the time of day, can contribute to better sleep quality. Establishing a consistent exercise routine is often more important than the specific time of day. Cons: Stimulating effect: For some people, intense exercise close to bedtime may have a stimulating effect, making it more challenging to wind down and fall asleep. Body temperature: While the drop in body temperature after exercise can promote sleep, exercising too close to bedtime may disrupt the body’s natural cooling process, potentially interfering with sleep. Individual variability: People respond differently to exercise timing. Some may find that late-night workouts do not impact their sleep, while others may experience difficulties. Recommendations: Timing matters: Try to finish exercising at least 2-3 hours before bedtime to allow your body temperature to return to normal and your adrenaline levels to decrease. Listen to your body: Pay attention to how your body responds to evening workouts. It might be a good fit for you if it helps you relax and improves your sleep. Experiment: Everyone is different. Experiment with varying timings of exercise to see what works best for you. If evening workouts negatively impact your sleep, consider shifting them earlier. Moderation is key: Intense or vigorous exercise close to bedtime might be more likely to interfere with sleep. Opt for moderate-intensity activities in the evening (47). Nearly 50% of patients living with psoriatic arthritis report high levels of fatigue (five or higher on a 10-point scale) and consider fatigue a high-ranking problem, after joint pain and before skin issues (48). See related Key Facts section FATIGUE Problem solving, planning, prioritising, and pacing may help you cope better with your fatigue: PROBLEM SOLVING Identify factors / tasks / chores / activities that are contributing to your fatigue; Think about solutions that could help minimise the impact of these factors/tasks/chores/ activities. PLANNING Plan the tasks/chores/activities you want to complete in a day or week; Make sure to include activities that you enjoy and can improve your mood/wellbeing; Do not beat yourself up if you cannot stick to the plan. PRIORITISING Organise your tasks/chores/activities by order of importance. PACING Do not use your energy all in one go; Break the planned tasks/chores/activities into smaller portions that can be spread out over the course of a day, a week or even longer. See related Key Facts section EMOTIONAL WELLBEING Living with psoriatic arthritis can take a toll on your mental health (49, 50). You need to treat mental health symptoms as seriously as physical symptoms. Poor mental health can cause your psoriatic arthritis to flare, increase pain and fatigue, negatively affect your work and personal relationships, and limit your ability to manage your overall health. If you feel sad, hopeless, and lose interest in things you used to enjoy, talk to your doctor, and let your loved ones know what you are going through. Your doctor may redirect you to useful mental health services such as cognitive behavioural therapy (CBT) and/or they may prescribe you an antidepressant. h3.3 h3.4 Remember that you are not alone. If you need extra support, we are here to help you: NHS Mental Health Services https://www.nhs.uk/nhs-services/mental-health-services/ VERSUS ARTHRITIS / Psoriatic arthritis https://versusarthritis.org/ +44 800 520 0520 Be kind to your joints and your mind. See related Key Facts section See related Key Facts Previous page Next page

iPROLEPSIS project will perform four different clinical studies in four different counties. Learn more about clinical studies by visiting iprolepsis.eu. About clinical studies iPROLEPSIS will perform four different clinical studies: 1. iPROLEPSIS-PDPID PsA digital phenotyping and inflammation drivers study. 2. iPROLEPSIS-MOJMI Mast cells and optoacoustics-enabled joint and microvascular imaging study. 3. iPROLEPSIS-IDBV Inflammation digital biomarkers validation study. 4. iPROLEPSIS-PPIDC Prevention of PsA inflammation through digital care: an intervention study. Clinical studies will be conducted in 5 countries: Netherlands UK Portugal Greece Germany Clinical studies PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) Development cohort of smartphone and smartwatch-based, AI-driven digital biomarkers for remote assessment and monitoring of people with psoriatic arthritis. Measure To develop novel smartphone- and smart device (belt, ring, camera) digital biomarkers for the assessment of inflammatory symptoms with special focus on the recognition of changes in movement patterns, pain, fatigue, morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. OBJECTIVES Primary objectives • to provide accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch[1] based, AI-driven digital biomarker system in the detection of PsA specific inflammation; • to predict accurate, factual and clinically relevant PsA specific inflammation. Secondary objectives • to determine interperson reliability of the AI-driven digital biomarker system; • to determine construct validity against clinical assessment of inflammation; • to determine construct validity against patient assessment of inflammation; • to determine clinically relevant changes in the AI-driven digital biomarker system; • to determine minimal detectable difference in the AI-driven digital biomarker system; • to assess the interperson variation of stress, mechanical stress and changes in gut microbiome on the occurrence of inflammation; • to evaluate the compliance and satisfaction of the users with the smartphone and smartwatch-based, AI[1] driven digital monitoring system. The study is designed to develop a new way of measuring inflammation in patient with psoriatic arthritis. Definition of novel optoacoustic biomarkers of psoriasis and psoriatic arthritis (iPROLEPSIS-MOJMI) Mast cells and optoacoustics-enabled joint and microvascular imaging (iPROLEPSIS-MOJMI) study. The proposed multiscale (mesoscopic with RSOM and macroscopic with MSOT) approach aims at exploring and defining novel image-based biomarkers in order to describe the pathophysiological changes characterizing the disease and predict the transition from PsO to PsA. In other words, the unique multiscale nature of optoacoustics is expected to render skin microvasculature a window to later systemic (joint) effects of psoriasis and, thus, improve the prognosis in future patients with PsO. OBJECTIVES Primary objectives • To define novel inflammatory mast cell, MSOT- and RSOM extracted biomarkers in patients with PsO/PsA. • To quantify the changes of the novel inflammatory mast cell, MSOT- and RSOM-extracted biomarkers' with increasing disease severity. Secondary objectives • To reveal correlations among the mast cells and the MSOT-and RSOM-extracted inflammatory biomarkers in patients with PsO/PsA. • To define a novel index derived from mast cells, MSOT- and RSOM-based features to enable the early detection of PsA in patients with PsO or high risk for developing PsO. Inflammation digital biomarkers validation study (iPROLEPSIS-IDBV) Finding people that will convert from healthy to inflamed is a difficult task in Immune Mediated Inflammatory Disease (IMID). Initial symptoms look just like any other musculoskeletal disorder such as back pain, finger pain or achilles tendon problems. Over time symptoms can go either temporarily away, become chronic or become so severe that doctor care is needed. Early identification of people with IMID would greatly benefit their quality of live, keeps them at work and prevents high health care cost due to expensive medication. Digital biomarkers will give us for the first time the ability to study the conversion from musculoskeletal disorder to immune mediated inflammatory joint and tendon disease. The aim of this study to validate our digital biomarkers findings in PsA in psoriasis patients. OBJECTIVES Primary objectives • to validate accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch-based, AI-driven digital biomarker system in the detection of IMID specific joint or tendon inflammation. Secondary objectives • to evaluate take up and acceptability of the digital biomarker in the wild; • to evaluate the impact of missing data in detecting inflammation; • to assess the number of false positives when data is captured in the wild; • to assess the interperson variation of stress and mechanical stress. The aim is to identify inflammation with a software based medical device. This software will consist of an algorithm analysing data collected in the wild via smart devices: phone, watch, ring. Prevention of PsA inflammation through digital care: an intervention study (iPROLEPSIS-PPIDC) This study blends the findings of the newly developed digital biomarkers, the early findings of the triggers: stress, mechanical stress and changes in microbiome from PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID), to provide a personalised approach to deal with the triggers with state-of-the-art interventions. OBJECTIVES Primary objectives In PsA patients with low disease activity a personalised intervention on food, physical activity and stress based on a personal profile of stress, mechanical stress and microbiome will be compared to usual care on inflammation development as detected by the newly developed digital biomarker system and clinical examination. Secondary objectives • to evaluate take up and acceptability of the digital biomarker and intervention as part of normal medical treatment among patients, doctors and nurses; • to assess compliance with the personalised intervention.

Ethics, legal and exploitation team Dr. Ioannis Drivas DIADIKASIA BUSINESS CONSULTING SYMVOULOI EPICHEIRISEON AE (DBC) Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Project Manager What are your main activities in the project? As Project Manager, I coordinate all iPROLEPSIS-related activities assigned to DBC. What is your motivation? My motivation stems from a strong commitment to upholding ethical and legal standards in research while maximizing the impact and real-world use of the iPROLEPSIS results. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK iPROLEPSIS presented at PhD DEI 2023 Nov 13, 2023 Highlights from PhD DEI 2023 Organised by the Universidade de Lisboa (the Instituto Superior Técnico), the PhD DEI 2023 event on 10 November 2023 served as a platform for introducing new PhD students to the Department of Engineering and Informatics (DEI). The event fostered an environment of knowledge-sharing and collaboration among students from the Doctoral Program in Computer Science and Engineering and the Doctoral Program in Digital Media. One of the standout presentations at PhD DEI 2023 was the poster presentation on the iPROLEPSIS Exergames. This presentation, delivered by Bárbara Ramalho, a PhD student from the FMH-ULisboa team, highlighted the general concepts and objectives of the iPROLEPSIS project. The iPROLEPSIS Exergames were developed through a co-design process, emphasizing collaborative and innovative approaches to game design aimed at promoting physical activity and health. Read more: We now know the audience's favorite posters from PhD DEI 2023! - Departamento de Engenharia Informática (DEI) ( ulisboa.pt ) 1/1 PREVIOUS NEXT

Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being. By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.